For individual cancers, GLP-1RA use showed a trend toward lower risk for pancreatic (HR, 0.88 [95% CI, 0.68–1.14]), bladder (HR, 0.83 [95% CI, 0.64–1.08]), and breast (HR, 0.93 [95% CI, 0.79–1.10]) cancer, though these differences were not statistically significant.
← all excerpts
Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.
1
—
—